Kim Chung Young, Kim Mee Kum
Department of Ophthalmology, Seoul National University Hospital, 101 Daehak-ro, Jongno-gu, Seoul, 110-744, South Korea.
Laboratory of Ocular Regenerative Medicine and Immunology, Biomedical Research Institute, Seoul National University Hospital, 101 Daehak-ro, Jongno-gu, Seoul, 110-744, South Korea.
BMC Ophthalmol. 2019 Mar 11;19(1):72. doi: 10.1186/s12886-019-1085-2.
To investigate the efficacy and safety of the retention ring-assisted continuous application of 0.1% riboflavin in pulsed-light accelerated corneal collagen cross-linking on the progression of keratoconus.
The medical records of 20 eyes of 18 patients with progressive keratoconus who received collagen cross-linking at Seoul National University Hospital were retrospectively reviewed. Isotonic 0.1% riboflavin was continuously applied for 10 min using an 8.0-mm retention ring before the irradiation and accelerated cross-linking was applied with 30-mW pulsed-ultraviolet light at a wavelength 365 nm for eight minutes (1 s on/1 s off; 30 mW/cm, cumulative dose of 7 .2J/cm) without further intermittent application of riboflavin. Visual acuity, refractive error, topographic index, corneal thickness, and endothelial cell density were evaluated before the operation and at 1, 3, 6, and 12 months.
The best corrected visual acuity in logMAR improved from preoperative 0.43 to 0.17 in 12 months (p = 0.050). Maximum keratometry decreased from 51.8 D to 50.4 D at 6 months (p = 0.015) and 50.1 D at 12 months (p = 0.0003). Astigmatism decreased from preoperative 5.5 D to 4.1 D at 12 months (p < 0.0001). Thinnest corneal thickness decreased at three and 6 months but recovered in 12 months (p > 0.05). Endothelial cell density decreased at postoperative 1 month (p = 0.02) but gradually recovered in 12 months (p > 0.05).
Retention ring-assisted continuous application of riboflavin for 10 minutes in pulsed-light accelerated cross-linking is a comparably safe and effective treatment for halting the progression of keratoconus in 12 months when compared to outcomes of the standard Dresden protocol shown in previous reports.
探讨在脉冲光加速角膜胶原交联中使用固定环辅助持续应用0.1%核黄素对角圆锥角膜进展的疗效和安全性。
回顾性分析首尔国立大学医院18例进行性圆锥角膜患者20只眼接受胶原交联治疗的病历。在照射前使用8.0毫米固定环持续应用等渗0.1%核黄素10分钟,然后用波长365纳米、功率30毫瓦的脉冲紫外光进行8分钟加速交联(1秒开/1秒关;30毫瓦/平方厘米,累积剂量7.2焦/平方厘米),无需进一步间歇应用核黄素。在手术前以及术后1、3、6和12个月评估视力、屈光不正、地形指数、角膜厚度和内皮细胞密度。
12个月时,最佳矫正视力(logMAR)从术前的0.43提高到0.17(p = 0.050)。最大角膜曲率在6个月时从51.8 D降至50.4 D(p = 0.015),在12个月时降至50.1 D(p = 0.0003)。散光在12个月时从术前的5.5 D降至4.1 D(p < 0.0001)。最薄角膜厚度在3个月和6个月时下降,但在12个月时恢复(p > 0.05)。内皮细胞密度在术后1个月下降(p = 0.02),但在12个月时逐渐恢复(p > 0.05)。
与先前报告中标准德累斯顿方案的结果相比,在脉冲光加速交联中使用固定环辅助持续应用核黄素10分钟是一种在12个月内阻止圆锥角膜进展的相对安全有效的治疗方法。